CD80 and neoplasm: In summary, the 8 mice treated with RP-B7-H3 CAR T with complete tumor rejection remained tumor-free and healthy, while the other mice treated with NRP-B7-H3 CAR T, derived from the same PBMCs had shorter survival (Fig. 6d).